Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Relapsed Wilms Tumor (NWTS-5)
NCT00002610Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Jan 1996
- Primary completion
- Jun 2002
- Modality
- DNA Intercalators/Alkylators
- Countries
- 7
01
Overview
Phase 3, open-label trial of carboplatin, etoposide and cyclophosphamide in Wilms' tumor, clear cell sarcoma of the kidney (CCSK) and Rhabdoid Tumor of the Kidney (RTK) (4 arms), sponsored by Children's Oncology Group. Primary endpoint: Event-Free Survival at 2 years. Started Jan 1996; status: completed.
02
Drugs
carboplatinetoposidecyclophosphamide
03
Conditions
Wilms' tumorclear cell sarcoma of the kidney (CCSK)Rhabdoid Tumor of the Kidney (RTK)
Beyond the preview
Go deeper on NCT00002610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002610.